The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States
Clin Gastroenterol Hepatol. 2021 Oct 16;S1542-3565(21)01131-9. doi: 10.1016/j.cgh.2021.10.018.
Zobair M Younossi1, Michael Harring2, Youssef Younossi3, Janus P Ong4, Saleh A Alqahtani5, Maria Stepanova6
Author information
1Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia; Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia; Inova Medicine, Inova Health System, Falls Church, Virginia. Electronic address: Zobair.Younossi@inova.org.
2Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia.
3Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia.
4College of Medicine, University of the Philippines, Manila, Philippines.
5Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland; Center for Outcomes Research in Liver Diseases, Washington, District of Columbia.
6Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia; Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia; Center for Outcomes Research in Liver Diseases, Washington, District of Columbia.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide.1,2 It is believed that about one fourth of the world population may have NAFLD.3 The Global Burden of Disease data suggest that NAFLD and nonalcoholic steatohepatitis (NASH) are the main drivers of liver disease burden in most regions of the world, including that of hepatocellular carcinoma (HCC).4,5.